About: Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
Creator	Davis, Michael, J Rybak, Abdalhamid, M Estrada, Evan, D Joshua, R Lagnf, Melvin, Molly, E Rosenberg, Sahil, Bhatia Samuel, P Sandra, J Sarah, M Simon, Steed, Susan, L Taylor, Morrisette Trang, Sarah Zasowski, J
Source	PMC
abstract	BACKGROUND: The aim of this study was to evaluate the predictive performance of the INCREMENT-CPE (ICS), Pitt bacteremia score (PBS) and qPitt for mortality among patients treated with ceftazidime–avibactam for carbapenem-resistant Enterobacteriaceae (CRE) infections. METHODS: Retrospective, multicenter, cohort study of patients with CRE infections treated with ceftazidime–avibactam between 2015 and 2019. The primary outcome was 30-day all-cause mortality. Predictive performance was determined by assessing discrimination, calibration and precision. RESULTS: In total, 109 patients were included. Thirty-day mortality occurred in 18 (16.5%) patients. There were no significant differences in discrimination of the three scores [area under the curve (AUC) ICS 0.7039, 95% CI 0.5848–0.8230, PBS 0.6893, 95% CI 0.5709–0.8076, and qPitt 0.6847, 95% CI 0.5671–0.8023; P > 0.05 all pairwise comparisons]. All scores showed adequate calibration and precision. When dichotomized at the optimal cut-points of 11, 3, and 2 for the ICS, PBS, and qPitt, respectively, all scores had NPV > 90% at the expense of low PPV. Patients in the high-risk groups had a relative risk for mortality of 3.184 (95% CI 1.35–8.930), 3.068 (95% CI 1.094–8.606), and 2.850 (95% CI 1.016–7.994) for the dichotomized ICS, PBS, and qPitt, scores respectively. Treatment-related variables (early active antibiotic therapy, combination antibiotics and renal ceftazidime–avibactam dose adjustment) were not associated with mortality after controlling for the risk scores. CONCLUSIONS: In patients treated with ceftazidime–avibactam for CRE infections, mortality risk scores demonstrated variable performance. Modifications to scoring systems to more accurately predict outcomes in the era of novel antibiotics are warranted. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40121-020-00288-4) contains supplementary material, which is available to authorized users.
has issue date	2020-02-22(xsd:dateTime)
bibo:doi	10.1007/s40121-020-00288-4
has license	no-cc
sha1sum (hex)	30c3284e04cbdb656aeed06d00dd4ff7e3e57f5f
schema:url	https://doi.org/10.1007/s40121-020-00288-4
resource representing a document's title	Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
has PubMed Central identifier	PMC7223509
schema:publication	Infect Dis Ther
resource representing a document's body	covid:30c3284e04cbdb656aeed06d00dd4ff7e3e57f5f#body_text
is schema:about of	named entity 'Evaluation' named entity 'PREDICTIVE' named entity 'AIM' named entity 'STUDY' named entity 'EVALUATE' named entity 'aim' named entity 'evaluate' named entity 'Patients' named entity 'Carbapenem' named entity 'Ceftazidime' named entity 'Enterobacteriaceae Infections' named entity 'PBS' named entity 'Chronic pulmonary disease' named entity 'CRE' named entity 'treatment effect' named entity 'renal function' named entity 'confidence interval' named entity 'bacteremic' named entity 'avibactam' named entity 'univariate' named entity 'cohort study' named entity 'post-test probability' named entity 'bacteremia' named entity 'infection' named entity 'mortality risk' named entity 'infection' named entity 'comorbidity' named entity 'clinical studies' named entity 'avibactam' named entity 'continuous variable' named entity 'antibiotic' named entity 'carbapenemase' named entity 'CRE' named entity 'inherent bias' named entity 'avibactam' named entity 'carbapenemase' named entity 'informed consent' named entity 'ceftazidime' named entity 'Enterobacteriaceae' named entity 'randomly assigned' named entity 'NPV' named entity 'risk of death' named entity 'selection bias' named entity 'colistin' named entity 'sample size' named entity 'Descriptive statistics' named entity 'goodness-of-fit test' named entity 'PBS' named entity 'infection' named entity 'standard procedures' named entity 'mortality risk' named entity 'infection' named entity 'PBS' named entity 'PBS' named entity 'infection' named entity 'IRB' named entity 'NLR' named entity 'CRE' named entity 'CRE' named entity 'Poisson regression' named entity 'antimicrobial stewardship' named entity 'Creative Commons licence' named entity 'positive likelihood ratio'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software